Growth Metrics

Terns Pharmaceuticals (TERN) Depreciation & Amortization (CF) (2020 - 2023)

Terns Pharmaceuticals' Depreciation & Amortization (CF) history spans 4 years, with the latest figure at $72000.0 for Q4 2023.

  • For Q4 2023, Depreciation & Amortization (CF) fell 22.58% year-over-year to $72000.0; the TTM value through Dec 2023 reached $292000.0, down 39.67%, while the annual FY2025 figure was $90000.0, 71.79% down from the prior year.
  • Depreciation & Amortization (CF) reached $72000.0 in Q4 2023 per TERN's latest filing, roughly flat from $72000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $172000.0 in Q1 2021 to a low of $72000.0 in Q2 2023.
  • Average Depreciation & Amortization (CF) over 4 years is $105125.0, with a median of $103500.0 recorded in 2020.
  • Peak YoY movement for Depreciation & Amortization (CF): surged 95.45% in 2021, then plummeted 47.83% in 2023.
  • A 4-year view of Depreciation & Amortization (CF) shows it stood at $106000.0 in 2020, then rose by 7.55% to $114000.0 in 2021, then decreased by 18.42% to $93000.0 in 2022, then fell by 22.58% to $72000.0 in 2023.
  • Per Business Quant, the three most recent readings for TERN's Depreciation & Amortization (CF) are $72000.0 (Q4 2023), $72000.0 (Q3 2023), and $72000.0 (Q2 2023).